Navigation Links
Third Clinical Study Confirms Treatment Guided By GeneSight Psychiatric Pharmacogenomics Test
Date:12/5/2013

2012).  La Crosse was a large prospective clinical trial involving 227 participants in which the GeneSight-guided group experienced an overall greater than 2-fold improvement in both symptoms and likelihood to achieve remission. All three studies consistently showed a substantially greater baseline to endpoint decrease in depressive symptoms with higher rates of response and remission in the guided GeneSight group over empiric prescribing, which is the current standard of care. These results reinforce the benefit of GeneSight in providing more objective, evidence-based support for clinicians in selecting medications for patients with psychiatric disorders. 

About Assurex Health

Assurex Health is a personalized medicine company that specializes in pharmacogenomics and is dedicated to helping physicians determine the right medication for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Assurex Health has licensed technology from Mayo Clinic and Cincinnati Children's Hospital Medical Center. Mayo Clinic has a financial interest in the technology referenced in this news release.

For more information about Assurex Health, please visit www.assurexhealth.com.

About GeneSight

GeneSight is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, manufacturers' FDA approved drug labels, peer reviewed scientific and cl
'/>"/>

SOURCE Assurex Health
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
2. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
3. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
4. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
5. Cardica Announces Fiscal 2012 Third Quarter Financial Results
6. Hill-Rom Announces Third Quarter 2012 Dividend
7. Cardinal Health Reports Third-Quarter Results
8. TPI to Host Third Quarter of Fiscal Year 2012 Earnings Conference Call on Tuesday, May 15, 2012 at 9:00 a.m. ET
9. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
10. ThermoGenesis Corp. To Announce Third Quarter Fiscal 2012 Results On May 10, 2012
11. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... 15, 2014 The Cadence Fitness & Health Center ... the Medical Fitness Association, a non-profit organization assisting medically ... potential. The Cadence Fitness & Health Center is the ... second in the Chicagoland area. "The certification ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Hill-Rom Holdings, Inc., (NYSE: HRC ) ... the Credit Suisse,s 2011 Healthcare Conference in Phoenix on ... You are invited to listen to the live discussion ... access it directly at http://cc.talkpoint.com/cred001/110911a_ah/?entity=1_CIKQF3F .  A recorded ...
... 2011 Seven Summits Research issues critical PriceWatch Alerts for ... what our analysts have discovered about these stocks read the ... (Note: You may have to copy this link into your ... Alerts cover the following stocks: Intel Corporation (Nasdaq: ...
Cached Medicine Technology:Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research 2
(Date:7/10/2014)... (PRWEB) July 10, 2014 Thousands ... gather in Copenhagen this July 13-17 to reveal ... the world closer to breakthroughs in dementia science. ... world’s largest conference of its kind. , As ... serves as a catalyst for generating new knowledge ...
(Date:7/10/2014)... York, US (PRWEB) July 10, 2014 ... , Merrill DataSite recently streamed the live webinar ‘Capitalizing ... a discussion from a group of several M&A experts ... seeing in the broader energy transaction marketplace. These experts ... and how the deal market in this sector has ...
(Date:7/10/2014)... CBPartners, a global leader in consulting ... new website. The redesigned site boasts improved navigation ... the firm’s thought pieces, blog posts, and conference presentations. ... showcase our insights, capabilities, and to provide timely updates ... Officer, Cyrus Chowdhury. “An enhanced online presence is ...
(Date:7/10/2014)... Best Drug Rehabilitation , ... family close by during a stay in rehab ... not the process is successful, has launched an ... http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success Stories ... several Best Drug Rehabilitation graduates who wanted to ...
(Date:7/10/2014)... Washington, New York (PRWEB) July 10, 2014 ... firm dedicated to protecting the rights of victims ... couple has brought a lawsuit over allegations that ... her body by a power morcellator used during ... has been filed against Richard Wolf Medical Instruments ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:CBPartners Announces New Website 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
... In ... Dr. Abdul Rao , Chief Executive Officer and Chief Research Officer, the Institute ... cross-enterprise electronic platform for timely integration of patient-specific healthcare information. , ... (Vocus) December 14, 2009 -- In ...
... than white women to receive radiation therapy after a lumpectomy, ... to a new study by researchers at The University of ... its kind and the first to examine such racial disparities ... Cancer . It was first presented at the 2008 American ...
... technology could lead to quicker detection and treatment, study ... "nanosensors" can detect early signs of cancer in everyday ... sensors hunted for and picked up biomarkers for prostate ... of the Yale Institute for Nanoscience and Quantum Engineering ...
... SAN ANTONIO - In a large review of breast ... of Texas M. D. Anderson Cancer Center have identified ... long-associated with a favorable prognosis and multiple tumors undetected ... at the CTRC-AACR San Antonio Breast Cancer Symposium, is ...
... ... Treatment Program , ... (PRWEB) December 12, 2009 -- Eighteen year addiction ends at Narconon California Drug Treatment ... prescription drugs for the last eighteen years! Imagine finding that out just before Christmas. ...
... , MEXICO CITY, Dec. 11 Genomma Lab ... its,2010 earnings guidance. , Genomma Lab expects net ... of 2010, excluding possible acquisitions, and an EBITDA margin,between 25.0% and 26.0%, ... guidance. , The Company,s estimates are based on ...
Cached Medicine News:Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 2Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 3Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 4Health News:Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 2Health News:Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 3Health News:'Nanosensors' Spot Early Signs of Cancer 2Health News:M. D. Anderson study questions true favorability of rare breast cancer type 2Health News:Nurse Celebrates Son's Drug Addiction Recovery During Holidays 2
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Sleeve extends 3mm beyond end, .90mm (20G) probe, 1.4mm (17G) sleeve...
Ideal for short scleral tunnel and trabecular meshwork incisions...
Medicine Products: